source
- Merck to test experimental sac-TMT antibody-drug conjugate with Keytruda in lung cancer trialMerck announced it will start a clinical trial testing its experimental antibody-drug conjugate sac-TMT together with the immunotherapy Keytruda in patients with lung cancer. The study will assess…
- As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca mergerWhile both drugmakers face looming patent cliffs, analysts say joining forces could help Bristol Myers Squibb replenish its eroding portfolio—while the strategic case for AstraZeneca seems to be mo…